BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35814563)

  • 1. IFN-
    Jia H; Xie X; Wang L; Wang L; Che F
    Comput Intell Neurosci; 2022; 2022():5492602. PubMed ID: 35814563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
    Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
    J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
    Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA
    Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the canonical signaling pathway of interferon-gamma is associated with glioblastoma progression.
    Zamora-Salas SX; Macías-Silva M; Tecalco-Cruz AC
    Mol Biol Rep; 2024 Jan; 51(1):64. PubMed ID: 38170343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
    Ricklefs FL; Alayo Q; Krenzlin H; Mahmoud AB; Speranza MC; Nakashima H; Hayes JL; Lee K; Balaj L; Passaro C; Rooj AK; Krasemann S; Carter BS; Chen CC; Steed T; Treiber J; Rodig S; Yang K; Nakano I; Lee H; Weissleder R; Breakefield XO; Godlewski J; Westphal M; Lamszus K; Freeman GJ; Bronisz A; Lawler SE; Chiocca EA
    Sci Adv; 2018 Mar; 4(3):eaar2766. PubMed ID: 29532035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [IFN-γ induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].
    Yan Y; Zhao C; Yang R; Zhou T; Xu N
    Sheng Wu Gong Cheng Xue Bao; 2018 Dec; 34(12):2007-2015. PubMed ID: 30584711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
    Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
    Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
    Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
    BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 14. Escherichia coli K12 Upregulates Programmed Cell Death Ligand 1 (PD-L1) Expression in Gamma Interferon-Sensitized Intestinal Epithelial Cells via the NF-κB Pathway.
    Lee SA; Wang Y; Liu F; Riordan SM; Liu L; Zhang L
    Infect Immun; 2020 Dec; 89(1):. PubMed ID: 33046511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
    Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
    Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
    Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines.
    Owaki R; Deguchi T; Konnai S; Maekawa N; Okagawa T; Hosoya K; Kim S; Sunaga T; Okumura M
    Vet Comp Oncol; 2023 Jun; 21(2):279-290. PubMed ID: 36802270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
    Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
    Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.